November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
19 citations
,
August 2019 in “Dermatologic therapy” Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
December 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
45 citations
,
May 2019 in “International Immunology” The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
7 citations
,
June 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
63 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
4 citations
,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
3 citations
,
November 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.
June 2023 in “Dermatology and therapy” The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
October 2021 in “International Journal of Dermatology”
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
July 2023 in “The Egyptian Journal of Hospital Medicine ” The conclusion is that emotional support and a variety of treatments are important for alopecia areata, but more research is needed.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
1 citations
,
May 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
19 citations
,
January 2019 in “Ginekologia Polska” The combined Myo-inositol and D-chiro-inositol treatment improved weight, hormone levels, and skin conditions in women with PCOS.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
223 citations
,
February 2019 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
3 citations
,
February 2018 in “InTech eBooks” Traditional Chinese Medicine and acupuncture may improve Polycystic Ovarian Syndrome symptoms and reduce costs, but more research is needed.